| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.0082 | 0.9 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.0081 | 0.9 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | navitoclax:PLX-4032 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | 0.0086 | 0.9 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | AGK-2 | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | NVP-ADW742 | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |